Therapeutic chaperone effect of N-octyl 4-epi-β-valienamine on murine G(M1)-gangliosidosis (Q48603852)

13 February 2018

title

Therapeutic chaperone effect of N-octyl 4-epi-β-valienamine on murine G(M1)-gangliosidosis (English)

1 reference

13 February 2018

0 references

Yoshiyuki Suzuki

1

1 reference

13 February 2018

Satoshi Ichinomiya

2

1 reference

13 February 2018

Mieko Kurosawa

3

1 reference

13 February 2018

Junichiro Matsuda

4

1 reference

13 February 2018

Seiichiro Ogawa

5

1 reference

13 February 2018

Masami Iida

6

1 reference

13 February 2018

Takatoshi Kubo

7

1 reference

13 February 2018

Miho Tabe

8

1 reference

13 February 2018

Masayuki Itoh

9

1 reference

13 February 2018

Katsumi Higaki

10

1 reference

13 February 2018

Eiji Nanba

11

1 reference

13 February 2018

Kousaku Ohno

12

1 reference

13 February 2018

publication date

3 March 2012

1 reference

13 February 2018

Molecular Genetics and Metabolism

published in

1 reference

13 February 2018

volume

106

1 reference

13 February 2018

issue

1

1 reference

13 February 2018

page(s)

92-98

1 reference

13 February 2018

Cloning, sequencing, and expression of cDNA for human beta-galactosidase

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Alpha-galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Beta-galactosidase deficiency: an approach to chaperone therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Chemical modification of beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of N-alkanoyl and N-alkyl derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Chemical modification of the beta-glucocerebrosidase inhibitor N-octyl-beta-valienamine: synthesis and biological evaluation of 4-epimeric and 4-O-(beta-D-galactopyranosyl) derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Chemical chaperone therapy for brain pathology in G(M1)-gangliosidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Chemical chaperone therapy: clinical effect in murine G(M1)-gangliosidosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Beta-galactosidase-deficient mouse as an animal model for GM1-gangliosidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Fibroblast screening for chaperone therapy in beta-galactosidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Neurological manifestations of knockout mice with beta-galactosidase deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Motor and reflex testing in GM1-gangliosidosis model mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Sites and temporal changes of gangliosides GM1/GM2 storage in the Niemann-Pick disease type C mouse brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Convenient synthesis and evaluation of glycosidase inhibitory activity of alpha- and beta-galactose-type valienamines, and some N-alkyl derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Prevalence of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

GM1 gangliosidosis and Morquio B disease: an update on genetic alterations and clinical findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Sphingolipidoses in Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Phenotype determining alleles in GM1 gangliosidosis patients bearing novel GLB1 mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Chemical chaperone therapy: chaperone effect on mutant enzyme and cellular pathophysiology in β-galactosidase deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Effects of thiol protease inhibitors on intracellular degradation of exogenous beta-galactosidase in cultured human skin fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

N-octyl-beta-valienamine up-regulates activity of F213I mutant beta-glucosidase in cultured cells: a potential chemical chaperone therapy for Gaucher disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Galactonojirimycin derivatives restore mutant human beta-galactosidase activities expressed in fibroblasts from enzyme-deficient knockout mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Structural bases of GM1 gangliosidosis and Morquio B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Crystal Structure of Human -Galactosidase: STRUCTURAL BASIS OF GM1 GANGLIOSIDOSIS AND MORQUIO B DISEASES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

Bone marrow transplantation in canine GM1 gangliosidosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2012.02.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YMGME.2012.02.012

1 reference

13 February 2018

release_haeg6b7itneatebccyvdw3gcxa

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/haeg6b7itneatebccyvdw3gcxa

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

13 February 2018